Target acne more effectively with Benzalkonium Chloride
Discover how this well-established antimicrobial and biofilm-disrupting agent can enhance acne treatment outcomes by overcoming the limitations of traditional therapies like antibiotics and benzoyl peroxide—offering a safer, more stable, and patient-friendly alternative.
The infographic below presents key insights from clinical and formulation studies on the effectiveness of Benzalkonium Chloride against Cutibacterium acnes and Staphylococcus epidermis, its ability to maintain product stability, and its compatibility across various delivery formats. Results show improved lesion reduction, low irritation risk, and potential as both an active and a preservative.
Download the infographic in PDF format by clicking this link.
Pharmaceutical-grade quality BKC
Benzalkonium Chloride (BKC) can be integrated into a wide array of product formulations—from creams and lotions to gels and cleansers. Whether it is used as an active and/or a preservative excipient, pharmaceutical-grade quality BKC guarantees that formulators have access to a safe, effective ingredient supported by comprehensive documentation and a clear safety profile.
Explore our cGMP manufactured BKC portfolio or contact us to find out how Novo Nordisk Pharmatech can meet your quality and regulatory needs.
White paper: Targeting acne with BKC
Acne vulgaris is a common skin condition with significant physical and psychological impact. Traditional treatments like antibiotics and benzoyl peroxide are effective, but challenges like antibiotic resistance and biofilm formation reduce their long-term efficacy.
BKC, a quaternary ammonium compound with potent antimicrobial and biofilm-disrupting properties, is an alternative. This white paper summarizes the findings of a recent literature review on the use of BKC for treating acne, including its mode of action, clinical evidence, and additional considerations relevant to its application.
